Clearmind Medicine Inc., a clinical pharmaceutical company, has filed its unaudited condensed interim consolidated financial statements and Management's Discussion and Analysis for the three and nine months ended July 31, 2024, with the Canadian Securities Administration. The report, filed on September 16, 2024, is incorporated by reference into the company's Registration Statements on Form F-3 with the SEC. Clearmind Medicine, which focuses on developing psychedelic medicines for health issues like Alcohol Use Disorder (AUD), has completed several significant milestones. These include a Type A meeting with the FDA, a registered direct and private placement offering raising $2.4 million, and the signing of exclusive licensing agreements with BIRAD and Yissum Research Development Company. The company also announced patent approvals in China and the commencement...Show More

Clearmind Medicine Inc., a clinical pharmaceutical company, has filed its unaudited condensed interim consolidated financial statements and Management's Discussion and Analysis for the three and nine months ended July 31, 2024, with the Canadian Securities Administration. The report, filed on September 16, 2024, is incorporated by reference into the company's Registration Statements on Form F-3 with the SEC. Clearmind Medicine, which focuses on developing psychedelic medicines for health issues like Alcohol Use Disorder (AUD), has completed several significant milestones. These include a Type A meeting with the FDA, a registered direct and private placement offering raising $2.4 million, and the signing of exclusive licensing agreements with BIRAD and Yissum Research Development Company. The company also announced patent approvals in China and the commencement of a phase I/IIa clinical trial in Israel for AUD. Clearmind Medicine has delisted from the Canadian Securities Exchange, maintaining its NASDAQ listing under the symbol 'CMND'. The company's financials show a net loss for the three and nine months ended July 31, 2024, with research costs and general and administrative expenses being the major contributors to the loss.